Aktienanalyse zu Bioventus Inc. (BVS)BVSBioventus Inc.

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Bioventus Inc is a good buy right now due to its current price of $13.065, which is significantly below the analyst price target of $18, indicating a potential upside of about 37%. Additionally, the company has shown strong financial performance with a gross margin of 68.29% in Q2 2026 and a net margin of 23.63%, reflecting solid profitability. The main risk is the RSI at 45.101, suggesting that the stock is nearing oversold conditions, which could lead to volatility.